Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies

A Strzelczyk, S Schubert-Bast - CNS drugs, 2022 - Springer
The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

Vagus nerve stimulation and seizure outcomes in pediatric refractory epilepsy: systematic review and meta-analysis

P Jain, R Arya - Neurology, 2021 - AAN Enterprises
Objective We synthesized evidence for effectiveness of vagus nerve stimulation (VNS) as
adjuvant therapy in pediatric drug-resistant epilepsy (DRE) by obtaining pooled estimates …

Elucidating the potential side effects of current anti-seizure drugs for epilepsy

E Akyüz, B Köklü, C Ozenen… - Current …, 2021 - benthamdirect.com
Over the decades, various interventions have been developed and utilized to treat epilepsy.
However, the majority of epileptic patients are often first prescribed anti-epileptic drugs …

Development of SV2A ligands for epilepsy treatment: a review of levetiracetam, brivaracetam, and padsevonil

PP Wu, BR Cao, FY Tian, ZB Gao - Neuroscience Bulletin, 2024 - Springer
Epilepsy is a common neurological disorder that is primarily treated with antiseizure
medications (ASMs). Although dozens of ASMs are available in the clinic, approximately …

The latest advances in the pharmacological management of focal epilepsies in children: a narrative review

S Matricardi, G Scorrano, G Prezioso… - Expert Review of …, 2024 - Taylor & Francis
Introduction Focal epilepsy constitutes the most common epilepsy in children, and medical
treatment represents the first-line therapy in this condition. The main goal of medical …

Potential role of brivaracetam in pediatric epilepsy

A Verrotti, EA Grasso, M Cacciatore… - Acta Neurologica …, 2021 - Wiley Online Library
Brivaracetam (BRV) is a new antiseizure medication (ASM) that is currently approved for
adjunctive treatment in patients with focal onset seizures. Similarly to levetiracetam (LEV) …

Anti-seizure medications: challenges and opportunities

N Tandon, M Radosavljevic, D Vucevic… - CNS & Neurological …, 2024 - ingentaconnect.com
Epilepsy is a chronic neurological condition characterized by unprovoked, recurrent
seizures. There are several types of epilepsy, and the cause of the condition can vary. Some …

[HTML][HTML] Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence

A Russo, J Pruccoli, CA Cesaroni, LMB Belotti… - Seizure, 2022 - Elsevier
Purpose: To report the efficacy and tolerability of brivaracetam (BRV) in add-on therapy in
pediatric patients with severe drug-resistant epilepsy. Prognostic factors of clinical outcome …

An update on brivaracetam for the treatment of pediatric partial epilepsy

E Tulli, G Di Cara, G Iapadre, P Striano… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: Brivaracetam (BRV) is an antiseizure medication (ASM), which has been
approved as an adjunctive treatment in adults and pediatric patients aged four years and …

[HTML][HTML] Narrative review of brivaracetam for genetic generalized epilepsies

I Lince-Rivera, NM Córdoba, JSO De la Rosa - Seizure: European Journal …, 2022 - Elsevier
Background The licensed treatment options for genetic generalized epilepsies are limited
although many patients with these conditions require chronic pharmacological management …